Filing Analysis
Pelthos Therapeutics announced that CEO Scott Plesha will participate in one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026. The company also released an updated corporate presentation via its website and as an exhibit to the filing.
Key Facts
- CEO Scott Plesha to attend Piper Sandler Spring Biopharma Symposium on April 16, 2026, in Boston.
- Company made an updated investor presentation available on its website and as Exhibit 99.2.
- The filing is a standard Regulation FD disclosure under Item 7.01.
- Pelthos is an emerging growth company listed on the NYSE American under the ticker PTHS.
Pelthos Therapeutics Inc. announced the termination of Francis Knuettel II as Chief Financial Officer and the appointment of John M. Gay as his successor, effective April 10, 2026. Mr. Gay, who previously served as the company's SVP of Finance and Accounting, brings extensive experience from roles at Novan, Inc. and Deloitte.
Red Flags
- The outgoing CFO was 'terminated' rather than resigning, which can sometimes indicate performance issues or strategic shifts, despite the 'no disagreement' clause.
Key Facts
- John M. Gay appointed as CFO, Treasurer, and Secretary effective April 10, 2026.
- Francis Knuettel II terminated as CFO effective April 10, 2026.
- Mr. Gay's compensation includes an annual base salary of $425,000 and a target bonus of 40%.
- Mr. Gay joined the company in July 2025 and previously served as CFO of Novan, Inc. and LNHC, Inc.
- The company stated the termination of the former CFO was not due to any disagreement regarding operations, policies, or practices.
Pelthos Therapeutics Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, and released an updated corporate presentation.
Key Facts
- Financial results for the fiscal year ended December 31, 2025, were reported on March 19, 2026.
- The filing includes a press release (Exhibit 99.1) and an updated investor presentation (Exhibit 99.2).
- The company is an emerging growth company listed on the NYSE American under the ticker PTHS.
- The report was signed by Chief Financial Officer Francis Knuettel II.